TTD | Drug: D0XH9B

Drug General Information
Drug ID	D0XH9B
Former ID	DIB000311
Drug Name	Tabimorelin
Synonyms	NN-703; NNC-26-0703; Tabimorelin < Prop INN >; N-[5-Amino-5-methyl-2(E)-hexenoyl]-N-methyl-3-(2-naphthyl)-D-alanyl-N-methyl-D-phenylalanine methylamide
Drug Type	Small molecular drug
Indication	Growth hormone deficiency [ICD9: 253.0, 253.3; ICD10:E22.0, E23.0]		Phase 2	[525551]
Structure		Download 2D MOL 3D MOL
Formula	C32H40N4O3
Canonical SMILES	CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc2ccc3ccccc3c2<br />)N(C)C(=O)\\C=C\\CC(C)(C)N
InChI	1S/C32H40N4O3/c1-32(2,33)19-11-16-29(37)35(4)28(22-24-17-18-25-14-9-10-15-26(25)20-24)31(39)36(5)27(30(38)34-3)21-23-12-7-6-8-13-23/h6-18,20,27-28H,19,21-22,33H2,1-5H3,(H,34,38)/b16-11+/t27-,28-/m1/s1
InChIKey	WURGZWOTGMLDJP-ZCYANPAGSA-N
CAS Number	CAS 193079-69-5
PubChem Compound ID	9810101
Target and Pathway
Target(s)	Growth hormone secretagogue receptor type 1	Target Info	Modulator	[525551]
KEGG Pathway	cAMP signaling pathway
KEGG Pathway	Neuroactive ligand-receptor interaction
NetPath Pathway	Leptin Signaling Pathway
Reactome	Peptide ligand-binding receptors
Reactome	G alpha (q) signalling events
WikiPathways	GPCRs, Class A Rhodopsin-like
	Gastrin-CREB signalling pathway via PKC and MAPK
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 525551	Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol. 1999 Aug;141(2):180-9.
Ref 525551	Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol. 1999 Aug;141(2):180-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information